Ernest JP, Ni Goh JJ, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. bioRxiv [Preprint]. 2023 Jan 20:2023.01.18.524608. doi: 10.1101/2023.01.18.524608. Update in: Eur Respir J. 2023 Jun 15;: PMID: 36711493; PMCID: PMC9882354.
Archives: Publications
Publications
Pragmatic cluster-randomized trial of home-based preventive treatment for TB in Ethiopia and South Africa (CHIP-TB)
Malhotra A, Nonyane BAS, Shirey E, Mulder C, Hippner P, Mulatu F, Ratshinanga A, Mitiku P, Cohn S, Conradie G, Chihota V, Chaisson RE, Churchyard GJ, Golub J, Dowdy D, Sohn H, Charalambous S, Bedru A, Salazar-Austin N.
Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
Chang YS, Li SY, Pertinez H, Betoudji F, Lee J, Rannard SP, Owen A, Nuermberger EL, Ammerman NC.
Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents
Wen Y, Lun S, Jiao Y, Zhang W, Liu T, Yang F, Tang J, Bishai WR, Yu LF.
Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial
Araújo-Pereira M, Krishnan S, Salgame P, Manabe YC, Hosseinipour MC, Bisson G, Severe DP, Rouzier V, Leong S, Mave V, Sawe FK, Siika AM, Kanyama C, Dadabhai SS, Lama JR, Valencia-Huamani J, Badal-Faesen S, Lalloo UG, Naidoo K, Mohapi L, Kityo C, Andrade BB, Gupta A.
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda
Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi JR, Kunihira Tinka L, Kamya MR, Sohn H, Kiwanuka N, Katamba A, Cattamanchi A, Dowdy DW, Semitala FC.
Higher yield using an event-based vs. door-to-door approach for active case-finding for TB
Malhotra A, Mukiibi J, Kitonsa PJ, Nalutaaya A, Kamoga CE, Robsky KO, Isooba D, Nantale M, Nakasolya O, Kayondo F, Mukiibi M, Kiyonga R, Dowdy DW, Katamba A, Kendall EA.
Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine
Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, Marquez C, Armstrong DT, Opira B, Kamya MR, Phillips PPJ, Dowdy DW, Yoon C.
QuantiFERON Supernatant-Based Host Biomarkers Predicting Progression to Active Tuberculosis Disease among Household Contacts of Tuberculosis Patients
Daniel EA, Thiruvengadam K, Rajamanickam A, Chandrasekaran P, Pattabiraman S, Bhanu B, Sivaprakasam A, Paradkar M, Kulkarni V, Karyakarte R, Shivakumar SVBY, Mave V, Gupta A, Babu S, Hanna LE.
Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responses
Adeoye B, Nakiyingi L, Moreau Y, Nankya E, Olson AJ, Zhang M, Jacobson KR, Gupta A, Manabe YC, Hosseinipour MC, Kumwenda J, Sagar M.